Abstract Background Tissue factor pathway inhibitor (TFPI) has anti-proliferative and anti-migratory effects on cultured smooth muscle cells (SMC) in addition to its anti-thrombotic activity. Here, we assess how long locally delivered recombinant TFPI (rTFPI) remains detectable at the delivery sites and clarify the main mechanism by which rTFPI blocks neointimal growth in vivo. Methods The iliac arteries of 85 Japanese white rabbits were injured using a Cutting Balloon TM . First, to establish the efficacy of local delivery of rTFPI, 5 groups of 3 rabbits each were examined immediately or 1, 2, 4 or 7 days after delivery. They were treated locally with a total amount of 200 µg of rTFPI given at 40 µg per pulse per minute by means of a Pulse Spray TM catheter. Thereafter, 34 rabbits which had received 200 µg of rTFPI after cutting angioplasty were compared to the same number of controls regarding thrombosis, inhibition of neointimal proliferation and inflammation. Results A total of 2.6 ± 1.6 ng rTFPI persisted on the injured vessel 4 days after delivery. rTFPI was still present on 48 % of the cut sites 7 days after delivery, despite its short half-life in plasma. Thrombosis in the rTFPI-treated group was significantly reduced compared to the controls. The number of macrophages present within the media and intima was significantly decreased at day 7 after delivery of rTFPI. Furthermore, the number of Ki-67-positive cells 14 days after rTFPI delivery was significantly lower than in controls although there were no significant differences between them after 2 days. Conclusions Local delivery of rTFPI decreased the degree of neointimal formation 4 weeks after TFPI delivery because of anti-inflammatory and anti-proliferative effects in addition to, or rather than, via anti-thrombosis.
Introduction
Tissue factor pathway inhibitor (TFPI) consists of 276 amino acid residues with three Kunitz-type domains. The first and second Kunitz domains inhibit factor VIIa/tissue factor and factor Xa, respectively, thus inhibiting the initial reactions of the extrinsic blood coagulation pathways (9) . Several studies using the recombinant protein in animal models have demonstrated the effectiveness of TFPI as an antithrombotic agent (11, 16, 18, 19) . Furthermore, some researchers reported that TFPI inhibited neointima formation 3 or 4 weeks after angioplasty (3, 6, 10, 15, 19) although none of them demonstrated inhibition of neointimal growth within 2 weeks after delivery. We questioned the appearance of this effect three weeks or more from angioplasty rather than within two weeks because the turnover of TFPI was reported to be very high (13, 17) . Also, it is not known how long the effect of the administered TFPI persists in tissue after delivery. Consequently, we attempted to clarify whether TFPI, which was delivered into the media, continued to have the potential to inhibit growth of neointima. Previously reported methods of administration of rTFPI are not appropriate for clinical use and systemic administration requires large amounts of the factor. However, such reports did emphasize the effectiveness of rTFPI for preventing restenosis after balloon angioplasty in animal models (3, 6, 10, 15, 19) .
In this study, we evaluated the efficacy of a local delivery system, which has potential practical clinical application, utilizing small amounts of rTFPI. Therefore, the aim of this study was to assess the main mechanism of suppression of neointimal growth by local delivery of rTFPI.
Materials and methods

Animals
All studies were performed with the approval of and with adherence to the guidelines of the National Cardiovascular Center Animal Care Committee. All rabbits were maintained under identical conditions of temperature (22 ± 2 °C), humidity (70 ± 5 %), and light/dark cycle and had access to a standard laboratory chow diet.
Materials
The full-length human rTFPI from Chinese hamster ovary cells was prepared as previously described (8) .
Measurement of human rTFPI adhering to the injured artery and in rabbit plasma
Human rTFPI on the injured arteries was measured by the following four steps as previously reported (3) . First, the resected arteries were incubated for 2 minutes at room temperature with 2 ml of 50 mM Tris with 200 mM NaCl (pH 7.4) (TBS) containing 5 U/ml heparin to detach glycosaminoglycan bound-rTFPI (Step 1). The extraction fluid was collected and centrifuged at 10,000 X g for 5 minutes. Arteries were then incubated for 2 minutes at room temperature with TBS containing 10 mM/l EDTA to detach tissue factor-factor VIIa-bound rTFPI. The extraction fluid was collected and centrifuged at 10,000 X g for 5 minutes (Step 2). To obtain phospholipidbound rTFPI, the arteries were again incubated in 2 ml of TBS containing 10 mM/l EDTA, 50 mM/l benzamidine, and 0.5 % Triton X-100 for 15 minutes at 0 °C, and the extraction fluid was collected and centrifuged in the same manner (Step 3). Furthermore, arteries were homogenized using a Politrone homogenizer with 1 ml of TBS at 0 °C to collect the rTFPI that remained on the tissues and could not be obtained by the above 3 processes. The extraction fluid was collected and centrifuged at 3,000 X g for 15 minutes at 0 °C (Step 4).
The extraction fluid obtained from each of the four steps was diluted with 50 mM HEPES, 1.0 M NaCl and 1% bovine serum albumin (pH 7.4) 5 times, 2 times, 2 times and 5 times, respectively. The amount of rTFPI antigen was determined by a sandwich enzyme-liked immunosorbent assay (ELISA) using monoclonal and polyclonal antibodies to human rTFPI as previously described (1) . Human rTFPI in rabbit plasma was also measured by a sandwich ELISA method.
Perfusion fixation and histological preparation
Rabbits were sacrificed by an overdose of pentbarbital sodium. Before excision, the injured arteries were fixed for 18 h with 4 % paraformaldehyde/citrate buffer with 20 mM CaCl 2 and 0.05 % glutaraldehyde at physiologic pressure, and then separated into 3 sections, 3 -4 mm in length, perpendicular to the long axis of the vessel in the middle of the injured area. The arterial segments were embedded in paraffin. The deparaffinized 5 µm thick sections were stained with Masson trichrome and elastica van Gieson's techniques.
Morphometric analysis
Three transverse sections of each rabbit's iliac artery were analyzed morphometrically. With NIH Image version 1.56 software, morphometric measurements of the neointima area and the media area were made. Data for each rabbit were obtained by averaging the calculated data from three sections.
Immunohistochemistry
After deparaffinization of the 5 µm thick sections, rTFPI was detected by standard LSAB methods with a polyclonal guinea pig anti-human rTFPI antiserum (ChemoSero-Therapeutic Research Institute, Kumamoto, Japan) as the primary antibody and biotinylated goat antiguinea pig IgG (H&L) antibodies (American Qualex, San Clemente, CA, USA) as the secondary antiserum. To identify macrophages, monoclonal mouse anti-rabbit macrophage (DAKO, Carpinteria, CA, USA) was used as the primary antibody. Ki-67-positive cells were identified using MIB-1 monoclonal antibody (Immunotech Co., Marseille, France) with wet heating pretreatment with 10 mM/l citrate buffer, pH 6.0 (2). A biotin-conjugated polyclonal goat anti-mouse IgG (Fc) (Harlan Sera-Lab, Ltd., Godgeford Lane, Belton, Loughborough, Leicestershire, UK) was used as the secondary anti-serum.
Cutting angioplasty
A total of 85 Japanese white rabbits (weight, 2.5 -2.9 kg) were anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg) and locally anesthetized with lidocaine (10 mg). After the right superficial femoral arteries were exposed and isolated, the Cutting Balloon TM (InterVentional Technologies Europe, Ltd., Donegal, Ireland) (4) was inserted into the iliac artery by the over-the-wire technique. The balloon, which was 2.5 mm in diameter, was inflated twice at 6 atmospheres for 120 seconds. Since no bleeding into the retroperitoneum was observed by arteriography after these procedures, the superficial femoral artery was ligated.
Efficacy of local delivery in situ of full-length human rTFPI to the vessel wall
The Pulse Spray TM catheter (3 F) (Angiodynamics, Inc., Glens Falls, NY) (5) with a 0.018 guide wire was used as a local drug delivery system to angioplasty sites. Drugs were delivered through longitudinal slits which were located at 90°intervals around the catheter end and which were 1 mm long and were present at 4 mm intervals within the area 2 cm from the catheter end. This was achieved by pushing the plunger at a 1 ml setting on the syringe by hand. Immediately after angioplasty, 40 µg of human rTFPI (a total amount of 200 µg) in 1 ml of 1 % albumin was sprayed 5 times every 1 minute through the Pulse Spray TM catheter at the injured site of the iliac artery (Fig. 1) .
To evaluate the efficacy of local delivery of human rTFPI across the physiological blood stream, blood samples were obtained from the femoral artery before drug delivery and upon sacrifice. The iliac arteries (approximately 4 cm in length) to which TFPI was delivered were excised to determine the amount of delivered/remaining TFPI. Three rabbits were sacrificed in each interval; immediately, 1 day, 2 days, 4 days or 7 days, respectively, after local drug delivery. One rabbit in which 5 ml of 1 % albumin was delivered was used as a control.
Effect of local delivery of human rTFPI
After angioplasty, the rTFPI group received 200 µg of human rTFPI (40 µg/administration/time). The control group received 5 ml of 1 % albumin by the same method. As acute effects, thrombi formation and the rate of remaining human rTFPI in the internal elastic laminae cut sites were assessed immediately (n = 4 in each group), 2 days (n = 6 in each group) and 7 days (n = 8 in each group) after angioplasty. Additionally, to examine and exclude any injury to the artery caused by the local drug Whereas the left iliac artery is reflected in the angiogram, the right iliac artery and terminal aorta were not reflected for several seconds due to powerful delivery of human rTFPI. Each interval on the scale on the left side represents 5 mm in length. C Catheter end of Pulse Spray TM catheter. By pushing the 1 ml syringe, the drug is ejected from 16 slits. Four slits are located at 90° intervals around catheter and are present at 4 mm intervals within the area 2 cm from the catheter end. Bl bladder.
delivery system itself, the iliac artery of one rabbit was evaluated after rTFPI delivery without angioplasty. As to the chronic effects of rTFPI, the neointima/media area ratio was evaluated 14 (n = 8 in each group) and 28 (n = 8 in each group) days after angioplasty. Furthermore, to assess the influence of TFPI on inflammation, rabbit macrophages were identified by immunohistochemistry and the average number of macrophages among three arterial cross sections for each rabbit was calculated. Ki-67-positive cells were also compared in the two groups.
Statistics
The data are expressed as mean ± SD. The independent variable for each factor between the rTFPI group and control group (thrombi formation rate and stained sites with anti-human rTFPI antibody) was analyzed by Fisher's exact test. The number of macrophages and Ki-67-positive cells were evaluated by one-way analysis of variance. Data of the neointima/media area ratio were analyzed by the unpaired t test if they showed homoscedasticity. Data without homoscedasticity were evaluated by the Welch's test.
Results
Efficacy of local delivery in situ of human rTFPI using the Pulse Spray TM catheter
Immediately after local delivery, 241.7 ± 123.5 ng of rTFPI was found to be attached to the injured vessels. On the other hand, 543.0 ± 81.8 ng/ml of rTFPI was present in rabbit plasma immediately after delivery. Although the rTFPI in rabbit plasma had disappeared by 2 days after delivery, 2.6 ± 1.6 ng of the delivered rTFPI remained present locally at the injured vessel for 4 days ( Table 1) . rTFPI was not detected in a control rabbit.
Acute effect of local delivery in situ of human rTFPI with regard to antithrombotic action
A control rabbit not treated with the Cutting Balloon TM showed no evidence of vessel injury caused by the use of the local delivery system employed here. The rTFPI group significantly suppressed thrombus formation compared to the control group (Table 2) . Immediately after angioplasty, there was strong and selective staining in the injured media sprayed with rTFPI (Table 2) (Fig. 2A, B) . rTFPI was detected in the subendothelium and matrix of the media in 48 % of cut sites of the rTFPI group at 7 days after treatment (Fig. 2C,  D) . One rabbit in each group died because of bleeding within 48 hours after balloon injury. The limit of detection of rTFPI in the extraction fluids obtained from steps 1 and 4 or 2 and 3 was 1.5 ng/ml and 0.6 ng/ml, respectively. rTFPI human recombinant tissue factor pathway inhibitor; Immed. Immediately 
Blockade of inflammation and anti-proliferative effects of the delivered human rTFPI
In the control group, the number of macrophages in both the intima and media was significantly greater 7 days after angioplasty than at the other time periods examined. The appearance of macrophages at this time point was significantly suppressed by treatment (Fig. 3) . The numbers of Ki-67-positive cells 2 days after angioplasty were nearly equal between the two groups. However, Ki-67-positive cells were not increased from 7 days after angioplasty in the rTFPI group. Consequently, Fig. 2C . The delivered rTFPI remained within the deep portion of injured media for which endothelia covered the exposed surface. Double arrow shows the edge of the cut internal elastic laminae. Scale indicates 100 Ȑm in length. M media; A adventitia. Fig. 3 A comparison of macrophages positive cells between the two groups. The rTFPI-treated group suppressed the infiltration of macrophages at 7 days after rTFPI delivery in the media and intima, respectively. *; p < 0.01 vs. control, **; p < 0.05.
Ki-67-positive cells in the rTFPI group were significantly decreased compared to the control group 14 days after angioplasty (Fig. 4) .
Chronic effect of local delivery in situ of human rTFPI with regard to inhibition of neointima formation
Typical sections from the two groups 28 days after angioplasty are shown in Fig. 5 . Concerning the inhibition of neointima formation, at 14 days after angioplasty, the neointima/media area ratios of the two groups were almost the same (0.119 ± 0.084 in the rTFPI group vs. 0.129 ± 0.097 in the control group). However, 28 days after angioplasty, the ratio in the rTFPI group (0.118 ± 0.130) was significantly lower than in the control group (0.342 ± 0.219) (p = 0.030).
Discussion
The main findings of the present study are 1) that the appearance of Ki-67-positive cells was significantly inhibited 2 weeks after rTFPI delivery, but not in the early phase, 2) macrophage infiltration was inhibited at day 7 after rTFPI delivery, and 3) consequently, the intima/ media area ratio was decreased 4 weeks after rTFPI delivery. The present study showed that 241.7 ± 123.5 ng of delivered human rTFPI (amount used: 200 µg) could adhere to endothelium, the matrix of media and cell surfaces immediately after delivery, even though this delivery system released the TFPI at the injured sites under a physiological blood stream for several seconds. Nevertheless, rTFPI was able to access the deeper portions of the injured vessels. Surprisingly, it was still detectable by immunohistological techniques 7 days after delivery. Asada et al. (3) had previously reported success in delivering 9.93 ± 4.21 ng of human rTFPI (100 µg/kg) to injured aorta, which remained present for 20 minutes after local delivery. However, they had prevented blood flow for one minute during delivery, using a Swan-Gantz catheter. This difference in efficacy of the local delivery system might be due to differences in the animal model used. Thus, Asada et al. (3) used the double balloon injury model, but we used the Cutting balloon TM , which exposed media easily with less vessel injury. This latter model forms a fibrin thrombus easily and the neointima has few elastic fibers, just as is observed in clinical restenosis in humans. However, the balloon over-stretch approach in rabbits results in the production of many elastic fibers in the neointima compared to the effect of injury with the Cutting balloon TM (data not shown). The nature of the local delivery system might also contribute to these differences, as it delivers rTFPI to the media in a less injurious manner. Finally, this recombinant protein might have the property of rapid and strong binding to the matrix and cell surfaces when delivered to a broad area by a method such as the one used here, employing a burst to the vessel walls.
Zoldhelyi et al. (21) reported that when adenovirusvectored TFPI was used for gene transfer to canine vascular SMC, TFPI secretion peaked at 4 days and declined thereafter. Their data can be interpreted to imply that if TFPI is present in the media over 4 days after angioplasty, it can suppress neointimal proliferation independently of anti-thrombotic effects. Some investigators reported that human rTFPI inhibited the growth of neointima from 3 weeks after angioplasty (3, 6, 10 ). In the current study, the number of Ki-67-positive cells was decreased compared to controls in the late phase. These results support the hypothesis that residual TFPI blocks late-phase neointima growth, but not immediately after angioplasty. Also of interest is the finding that macrophage infiltration was suppressed 7 days after recombinant TFPI delivery. One mechanism for blockade of neointima growth by long-lasting rTFPI might be via neutralization of inflammation after balloon injury.
In the model used in this study, human rTFPI inhibited the formation of mural thrombi at an early stage. The antithrombotic effects of rTFPI have been confirmed in several animal models (3, 11, 16, 18, 19) . The present results also indicate that rTFPI can be delivered effectively through a local drug delivery system, the same technique as in clinical use.
From these findings, we propose the following hypothesis: TFPI inhibits neointima formation after angioplasty by an antithrombotic action. When SMC are up-regulated by selected stimulators, if TFPI is bound to the matrix or cell surfaces and if it remains several days in the injured sites, it could inhibit or stop the growth of neointima through the suppression of SMC proliferation and migration, and/or neutralization of inflammation as a direct effect of rTFPI. This hypothesis is supported by in vitro studies, such as those showing that TFPI inhibited proliferation (12) or migration (19, 20) of cultured SMCs.
Recently, drug elution with stent therapy is emerging as one candidate for the prevention of restenosis after percutaneous coronary intervention. Several approaches to this problem are being investigated (7, 14) . If TFPI can be easily mounted on the stents, this might represent a powerful method for preventing restenosis as a novel alternative approach to current local drug delivery systems.
The present cutting balloon model resulted in less vessel injury compared to the over-stretched balloon model. Consequently, the beneficial effect of rTFPI, presented in this study, might be limited to this case of more minor vessel injury.
In conclusion, some of the locally delivered rTFPI persisted for 7 days after delivery. This persisting rTFPI suppresses macrophage infiltration at day 7 after delivery and prevents the increase of Ki-67-positive cells from 7 days after delivery. This local drug delivery system utilizing small amounts of rTFPI may have practical clinical application for the prevention of restenosis after percutaneous coronary intervention.
